current page

Newsroom 2017

December 13, 2017

Terumo Constructs a New Building in Yamaguchi, Japan
To Strengthen Production Operations in Interventional Systems

TOKYO, JAPAN – December 13, 2017 – Terumo Corporation (TSE: 4543) today announced that it will construct a new building for manufacturing interventional systems products on the property of Terumo Yamaguchi Corporation. Terumo will hire approximately 700 associates and invest a total of approximately 30 billion yen in the facility. Construction work is scheduled for June 2018 to October 2019, and operations are scheduled to commence in April 2021.

Terumo Yamaguchi manufactures access guidewires used in interventional procedures. The new building will be the company's third such structure. The company plans to increase the number of guidewire products it produces, as well as its total production capacity. The area of the new building will be approximately 50,000 square meters, or over three times the size of the site's first building, which currently manufactures guidewires.

Terumo has "Strengthen Global Operations" as one of key initiatives towards sustainable growth. The new building will strengthen production capacity in a growing field and optimize production on a global and group basis. The Terumo Interventional Systems Division leads Terumo group in revenue growth, and the construction is expected to support business growth in the globally growing interventional market.

As a global corporation with unique excellence, Terumo aims to become a top brand trusted in medical settings all over the world, through providing "Total Quality": high quality in all aspects of product, supply, and service.

About Terumo Corporation

Tokyo-based Terumo Corporation is one of the world's leading medical device manufacturers, with over $5 billion in sales and operations in more than 160 nations. Founded in 1921, the company develops, manufactures and distributes world-class medical devices, including products for use in cardiothoracic surgery, interventional procedures and transfusion medicine; the company also manufactures a broad array of syringe and hypodermic needle products for hospital and physician-office use. Terumo contributes to society by providing valued products and services to the health care market, and by responding to the needs of health care providers and the people they serve. Terumo Corporation's shares are listed on the first section of the Tokyo Stock Exchange (No. 4543, Reuters symbol <4543.T>, or Bloomberg 4543: JP) and is a component of the Nikkei 225, Japan's leading stock index.

(Notice) Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts on projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition. The market share information in this press release is partly derived from our own independent research.


Return to page top